GEP20012500B - Inhibitors of Protein Farnesyl Transferase - Google Patents
Inhibitors of Protein Farnesyl TransferaseInfo
- Publication number
- GEP20012500B GEP20012500B GEAP19974612A GEAP1997004612A GEP20012500B GE P20012500 B GEP20012500 B GE P20012500B GE AP19974612 A GEAP19974612 A GE AP19974612A GE AP1997004612 A GEAP1997004612 A GE AP1997004612A GE P20012500 B GEP20012500 B GE P20012500B
- Authority
- GE
- Georgia
- Prior art keywords
- inhibitors
- farnesyl transferase
- protein farnesyl
- composition
- protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1611096P | 1996-05-22 | 1996-05-22 | |
| US3366296P | 1996-12-17 | 1996-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20012500B true GEP20012500B (en) | 2001-07-25 |
Family
ID=26688183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP19974612A GEP20012500B (en) | 1996-05-22 | 1997-04-29 | Inhibitors of Protein Farnesyl Transferase |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0938494A1 (enExample) |
| JP (1) | JP2000511527A (enExample) |
| CN (1) | CN1219174A (enExample) |
| AU (1) | AU728477B2 (enExample) |
| BG (1) | BG102936A (enExample) |
| BR (1) | BR9709354A (enExample) |
| CA (1) | CA2253934A1 (enExample) |
| CO (1) | CO4960642A1 (enExample) |
| CZ (1) | CZ376498A3 (enExample) |
| EA (1) | EA199801031A1 (enExample) |
| EE (1) | EE9800408A (enExample) |
| GE (1) | GEP20012500B (enExample) |
| IL (1) | IL126833A0 (enExample) |
| NO (1) | NO985405L (enExample) |
| NZ (1) | NZ332712A (enExample) |
| PL (1) | PL330120A1 (enExample) |
| SK (1) | SK161098A3 (enExample) |
| WO (1) | WO1997044350A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027854A1 (en) * | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5968965A (en) * | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6066738A (en) * | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6028201A (en) * | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
| US6737410B1 (en) | 1997-04-11 | 2004-05-18 | Warner-Lambert Company | Inhibitors of protein farnesyl transferase |
| US6265382B1 (en) * | 1997-04-11 | 2001-07-24 | Warner-Lambert Company | Dipeptide inhibitors of protein farnesyltransferase |
| US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| NZ507165A (en) * | 1998-04-27 | 2003-06-30 | Warner Lambert Co | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
| AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6316436B1 (en) | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2001230864A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2002188646A (ja) * | 2000-12-20 | 2002-07-05 | Nsk Ltd | 転がり軸受及び軸受装置 |
| US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
| WO2005049589A2 (en) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases |
| DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP5328640B2 (ja) | 2006-04-19 | 2013-10-30 | ノバルティス アーゲー | ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法 |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP3536690A1 (en) | 2007-01-10 | 2019-09-11 | MSD Italia S.r.l. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
| US8293769B2 (en) | 2007-05-21 | 2012-10-23 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| MX2012010617A (es) | 2010-03-16 | 2012-10-05 | Dana Farber Cancer Inst Inc | Compuestos de imidazol y sus usos. |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP4079856A1 (en) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012145471A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP2925888B1 (en) | 2012-11-28 | 2017-10-25 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3057955B1 (en) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| IL315837A (en) | 2017-04-13 | 2024-11-01 | Sairopa B V | Anti-SIRP-alpha antibodies |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033288A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| JPH09504277A (ja) * | 1993-09-30 | 1997-04-28 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼの阻害剤 |
| FI961819A7 (fi) * | 1993-11-05 | 1996-04-29 | Warner Lambert Co | Proteiini:farnesyylitransferaasin substituoidut di- ja tripeptidi-inhi biittorit |
| US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
-
1997
- 1997-04-29 IL IL12683397A patent/IL126833A0/xx unknown
- 1997-04-29 WO PCT/US1997/006591 patent/WO1997044350A1/en not_active Ceased
- 1997-04-29 AU AU28058/97A patent/AU728477B2/en not_active Ceased
- 1997-04-29 GE GEAP19974612A patent/GEP20012500B/en unknown
- 1997-04-29 JP JP09542369A patent/JP2000511527A/ja not_active Abandoned
- 1997-04-29 CA CA002253934A patent/CA2253934A1/en not_active Abandoned
- 1997-04-29 CZ CZ983764A patent/CZ376498A3/cs unknown
- 1997-04-29 BR BR9709354A patent/BR9709354A/pt not_active Application Discontinuation
- 1997-04-29 EP EP97922365A patent/EP0938494A1/en not_active Withdrawn
- 1997-04-29 PL PL97330120A patent/PL330120A1/xx unknown
- 1997-04-29 EE EE9800408A patent/EE9800408A/xx unknown
- 1997-04-29 NZ NZ332712A patent/NZ332712A/xx unknown
- 1997-04-29 SK SK1610-98A patent/SK161098A3/sk unknown
- 1997-04-29 CN CN97194835A patent/CN1219174A/zh active Pending
- 1997-04-29 EA EA199801031A patent/EA199801031A1/ru unknown
- 1997-05-26 CO CO97028769A patent/CO4960642A1/es unknown
-
1998
- 1998-11-19 BG BG102936A patent/BG102936A/bg unknown
- 1998-11-20 NO NO985405A patent/NO985405L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL126833A0 (en) | 1999-08-17 |
| AU2805897A (en) | 1997-12-09 |
| EP0938494A1 (en) | 1999-09-01 |
| CA2253934A1 (en) | 1997-11-27 |
| CN1219174A (zh) | 1999-06-09 |
| NZ332712A (en) | 2000-07-28 |
| BR9709354A (pt) | 1999-08-10 |
| AU728477B2 (en) | 2001-01-11 |
| PL330120A1 (en) | 1999-04-26 |
| SK161098A3 (en) | 2000-06-12 |
| EE9800408A (et) | 1999-06-15 |
| JP2000511527A (ja) | 2000-09-05 |
| NO985405D0 (no) | 1998-11-20 |
| CZ376498A3 (cs) | 1999-02-17 |
| NO985405L (no) | 1999-01-19 |
| CO4960642A1 (es) | 2000-09-25 |
| BG102936A (bg) | 1999-09-30 |
| WO1997044350A1 (en) | 1997-11-27 |
| EA199801031A1 (ru) | 1999-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20012500B (en) | Inhibitors of Protein Farnesyl Transferase | |
| GEP20032897B (en) | Epothilone Derivatives | |
| MD1616F2 (en) | Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment | |
| GEP20012375B (en) | Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same | |
| GR3036188T3 (en) | Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase | |
| MD1632G2 (ro) | Compuşi biciclici, metodă de inhibare a receptorulor tirozinkinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitelor şi de tratament al mamiferelor | |
| MY121548A (en) | Compounds and methods for the treatment of cancer | |
| GEP20022616B (en) | (54) Azepin Derivatives to Inhibiting Farnesyl Protein Transferase and Method for Treatment | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| DK0839154T3 (da) | Biologiske aktive peptider og præparater samt anvendelse deraf | |
| GEP20043163B (en) | Inhibitors of Caspases, Pharmaceutical Composition on its Base and Method for its Production | |
| MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
| MX9708401A (es) | Genes reguladores de la cromatina. | |
| DE69715000D1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| GEP20032953B (en) | Antitumor Agents | |
| AU6484994A (en) | Seed treatment using phosphorous acid or one of its salts, and seeds thus treated | |
| TR200001147T2 (tr) | Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı | |
| EP2258702A3 (en) | Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors | |
| UA27910C2 (uk) | Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с | |
| MY137303A (en) | Methods for treating proliferative diseases | |
| GEP20032914B (en) | Derivatives of 1,3,4-Oxadiazolone | |
| PL332240A1 (en) | Tricyclic compounds useful in inhibiting g-proteinic function and in treating proliferative diseases | |
| TR199901386T2 (en) | �midazopiridazinler. | |
| MY117925A (en) | Compounds for the inhibition of farnesyl protein transferase. | |
| DE69321096D1 (de) | Katecholamine-diphosphate und diese enthaltende arzneimittel |